The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Polymer-based drug delivery depots have been investigated over the last several decades
as a means to improve upon the lack of tumor targeting and severe systemic morbidities …

This guideline provides recommendations for diagnostic and therapeutic procedures for
patients with malignant gliomas. We differentiate evidence-based standards from …

Targeted delivery of therapeutic nanoparticles in a disease-specific manner represents a
potentially powerful technology especially when treating infiltrative brain tumors such as …

Glioblastoma is the most common and most aggressive primary brain tumor. Despite
maximum treatment, patients only have a median survival time of 15 months, because of the …

Background: Glioblastoma multiforme (GBM) is the most common and lethal primary
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …

Primary intracranial tumors of the brain structures, including meninges, are rare with an
overall five-year survival rate of 33.4%; they are collectively called primary brain tumors …

Glioblastoma is one of the most lethal human cancers, with poor survival despite surgery,
radiation treatment, and chemotherapy. Advances in the treatment of this type of brain tumor …

Glioblastoma is the most common primary malignant brain tumor in adults and is a
challenging disease to treat. The current standard of care includes maximal safe surgical …

Background High grade glioma (HGG) is an aggressive form of brain cancer. Treatment of
HGG usually entails biopsy, or resection if safe, followed by radiotherapy. Temozolomide is …